Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

BACKGROUND: Direct thrombin inhibitors may lead to falsely low fibrinogen results. The interference of bivalirudin on fibrinogen assays has not been thoroughly evaluated. This study investigates the interference of bivalirudin on fibrinogen detection and the potential use of activated carbon to address this issue. METHODS: Normal pooled plasma from 20 healthy subjects was spiked with increasing bivalirudin concentrations (0-6.4 μg/mL). Interference of bivalirudin on fibrinogen testing was evaluated by comparing three Clauss-method assays (HemosIL Fibrinogen-C XL; STA-Fibrinogen; Dade Thrombin) to an immunoassay (N Antiserum to Human Fibrinogen reagent, NAHF). Activated partial thromboplastin time (APTT) and fibrinogen results were analyzed before and after the addition of activated carbon (AC) to evaluate the absorption of bivalirudin by AC. RESULTS: The NAHF immunoassay remained unaffected by bivalirudin (p = 0.27). All three Clauss-methods assays showed a significant downward trend with the increase of bivalirudin concentration (STA-Fibrinogen: p = 0.012, Dade Thrombin: p < 0.001, Fibrinogen-C XL: p < 0.001). When compared to their respective baselines, STA-Fibrinogen exhibited a reduction of 16%, Dade Thrombin showed a reduction of 40%, and Fibrinogen-C XL displayed a decrease of up to 89%. Neither STA-Fibrinogen nor Dade Thrombin displayed a significant downward trend when the APTT ratio did not exceed 2.5. After the addition of AC, SynthASil APTT and HemosIL Fibrinogen-C XL levels of all samples containing varying concentrations of bivalirudin returned to near baseline. CONCLUSION: The influences of bivalirudin on fibrinogen assays vary significantly. Activated carbon can effectively remove bivalirudin from plasma, thereby eliminating its interference on fibrinogen testing.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

This study shows bivalirudin causes assay-dependent, concentration-dependent underestimation of fibrinogen in three Clauss-method tests but not in an immunoassay, and that adding activated carbon removes bivalirudin from plasma, restoring APTT and Fibrinogen-C XL results to near baseline.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Arzneimittelentwicklung“.

• Hirudotherapie in Medizin und Zahnmedizin — Jha K et al. (2015)
• Blutegeltherapie: eine Geschichte — Hyson J (2005)
• Hirudine der asiatischen medizinischen Blutegelart Hirudinaria manillensis: gleich und doch verschieden — Lukas P et al. (2019)
• Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia — Lu Z et al. (2018)
• Molekulardynamische und pharmakologische Untersuchungen an durch Protein-Engineering erzeugten Hirudin-Varianten von Hirudinaria manillensis und Hirudo medicinalis — Sun Y et al. (2022)
• Zellfreie Synthese der Hirudin-Variante 1 des blutsaugenden Egels Hirudo medicinalis — Wüstenhagen D et al. (2020)
• Produktion von Hirudin-Varianten durch gentechnisch veränderte mikrobielle Zellfabriken — Zhang J, Lan N (2018)
• Hirudin bei heparininduzierter Thrombozytopenie — Lubenow N, Greinacher A (2002)
• Hirudin verbessert die diabetische Nephropathie durch Hemmung der Gsdmd-vermittelten Pyroptose — Han J et al. (2023)
• Hirudin als alternatives Antikoagulans – eine historische Übersicht — Markwardt F (2002)

Alle von der ASH analysierten Studien →